| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/28/2008 | CA2659461A1 Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| 02/28/2008 | CA2659328A1 Compositions, suitable for oral administration, comprising a triazolo [4,5-d]pyrimidin derivate |
| 02/28/2008 | CA2658835A1 Use of pkc inhibitors in ocular diseases |
| 02/28/2008 | CA2658511A1 Treatment of cartilage disorders |
| 02/28/2008 | CA2658000A1 Use of cd83 in combination therapies |
| 02/28/2008 | CA2657316A1 Method for improving pharmacokinetics |
| 02/28/2008 | CA2657183A1 New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds |
| 02/28/2008 | CA2650658A1 Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane |
| 02/28/2008 | CA2648521A1 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-n0r-vitamin d compounds with a 1,1-dimethylpropyl side chain |
| 02/27/2008 | EP1892301A1 Method for evaluation of compound using rsk1 |
| 02/27/2008 | EP1892299A2 Sense mRNA therapy |
| 02/27/2008 | EP1892293A1 Transcription factor decoy |
| 02/27/2008 | EP1892289A2 Adipose tissue-derived stromal cells for the repair of corneal and intra-orbital defects and uses thereof |
| 02/27/2008 | EP1892250A2 CYR61 compositions and methods |
| 02/27/2008 | EP1892243A1 Polymorphic forms of ziprasidone sulphate salts |
| 02/27/2008 | EP1892241A1 Novel piperidine derivative |
| 02/27/2008 | EP1892239A1 Inhibitors of cytosolic phospholipase A2 |
| 02/27/2008 | EP1892238A1 1, 2-di(cyclic group)substituted benzene derivative |
| 02/27/2008 | EP1892233A1 New salts of the active component rasagiline |
| 02/27/2008 | EP1891974A1 Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| 02/27/2008 | EP1891973A1 Combinations comprising antimuscarinic agents and PDE4 inhibitors |
| 02/27/2008 | EP1891971A1 Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent |
| 02/27/2008 | EP1891970A1 Beta glucan-based vaccines free of mannoprotein |
| 02/27/2008 | EP1891967A1 Long-lasting absorption of flavonoids |
| 02/27/2008 | EP1891963A1 Use of antagonists of PPY receptors for treating visceral pain or visceral hypersensitivity |
| 02/27/2008 | EP1891961A1 Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection |
| 02/27/2008 | EP1891960A1 Pharmaceutical formula for treating skin disease |
| 02/27/2008 | EP1891959A1 Contraceptive compositions for decrease risk of inborn errors |
| 02/27/2008 | EP1891958A1 Rho/Rock/PI3/Akt kinase inhibitors for the treatment of diseases associated with protozoan parasites. |
| 02/27/2008 | EP1891957A1 Purified Compositions of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same in the Treament of Tumors |
| 02/27/2008 | EP1891956A1 Solubilization preparation |
| 02/27/2008 | EP1891955A1 Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
| 02/27/2008 | EP1891954A2 Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder |
| 02/27/2008 | EP1891953A1 Immune response modifier sterile formulations and methods |
| 02/27/2008 | EP1891952A1 Pharmaceutical composition |
| 02/27/2008 | EP1891951A1 Viral polymerase inhibitors |
| 02/27/2008 | EP1891950A1 Viral polymerase inhibitors |
| 02/27/2008 | EP1891949A1 Use of tricyclic indole derivatives for the treatment of muscular atrophy |
| 02/27/2008 | EP1891948A1 Treatment of neurological and neuropsychological disorders |
| 02/27/2008 | EP1891947A2 Use of (r)-verapamil for the treatment of abnormal increases in gastrointestinal motility |
| 02/27/2008 | EP1891946A1 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone |
| 02/27/2008 | EP1891945A1 Treatment and prevention of excessive scarring |
| 02/27/2008 | EP1891944A1 Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases |
| 02/27/2008 | EP1891943A2 Nanoparticles comprising chitosan and cyclodextrin |
| 02/27/2008 | EP1891940A1 Intrasynovial formulations of stanozolol |
| 02/27/2008 | EP1891937A1 Galenic formulations of aliskiren |
| 02/27/2008 | EP1891924A1 Composition for protection of body surface |
| 02/27/2008 | EP1891216A2 Hybrid interfering rna |
| 02/27/2008 | EP1891089A2 Hcv protease inhibitors in combination with food |
| 02/27/2008 | EP1891083A1 Cyclodextrin inclusion complexes and methods of preparing same |
| 02/27/2008 | EP1891082A1 Novel inhibitors of pyruvate kinase as therapeutic agents for cancer |
| 02/27/2008 | EP1891078A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| 02/27/2008 | EP1891076A1 Substituted tetrahydroquinolines |
| 02/27/2008 | EP1891075A1 Tricyclic spiro derivatives as crth2 modulators |
| 02/27/2008 | EP1891074A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 02/27/2008 | EP1891073A1 Novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives and their use as a medicament |
| 02/27/2008 | EP1891072A2 Substituted 7, 8-dihydro-1h-pyrimido[4,5-b][1,4] diazepin-4-amines as kinase inhibitors |
| 02/27/2008 | EP1891071A2 Cyclopropanecarboxylate esters of acyclovir |
| 02/27/2008 | EP1891070A1 Prodrugs of a2b adenosine receptor antagonists |
| 02/27/2008 | EP1891069A1 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| 02/27/2008 | EP1891068A1 Triazolopyridine derivatives as cannabinoid receptor 1 antagonists |
| 02/27/2008 | EP1891066A2 Compounds and compositions as protein kinase inhibitors |
| 02/27/2008 | EP1891065A1 Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders |
| 02/27/2008 | EP1891064A1 N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as ccr1 antagonists |
| 02/27/2008 | EP1891063A2 Bicyclic derivatives as modulators of ion channels |
| 02/27/2008 | EP1891061A1 N-(2, 2-dimethylpropyl) -6- (3-fluoro-5- ( (3-isoxazolylamino) carbonyl) -2-methylpheny l) -3-pyridinecarboxamide |
| 02/27/2008 | EP1891058A1 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| 02/27/2008 | EP1891057A1 Azab i cyclo [3 . 1 . 0] hexane derivatives as dopamin d3 receptor modulators |
| 02/27/2008 | EP1891056A1 Novel compounds |
| 02/27/2008 | EP1891055A2 Process for the preparation of losartan potassium |
| 02/27/2008 | EP1891054A1 Hydrates of alkaline-earth salts of irbesartan and the preparation thereof |
| 02/27/2008 | EP1891052A1 Tubulin inhibitor and process for its preparation |
| 02/27/2008 | EP1891051A2 Solid forms of 1-( 5-(ih-i , 2 , 4 -triazol- 5 -yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene |
| 02/27/2008 | EP1891050A1 New derivatives of pyrrolyltriazine together with methods for obtaining them and their use as protecting agents against uv radiation |
| 02/27/2008 | EP1891048A1 Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| 02/27/2008 | EP1891047A2 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents |
| 02/27/2008 | EP1891046A1 Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate |
| 02/27/2008 | EP1891042A2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their therapeutic use on the central nervous system |
| 02/27/2008 | EP1891041A1 METABOLITES OF 1- [-6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL]-3- [2- (4-METHYL-PIPERAZIN-I-YL) -BENZYL]-PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS |
| 02/27/2008 | EP1891039A1 Quinoline derivatives useful as modulators of ion channels |
| 02/27/2008 | EP1891038A2 Substituted n-arylpyrrolidines as selective androgen receptor modulators |
| 02/27/2008 | EP1891036A1 Alpha 7 nicotinic receptor selective ligands |
| 02/27/2008 | EP1891035A1 Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs |
| 02/27/2008 | EP1891029A1 Organic compounds for the treatment of imflammatory or alleric conditions |
| 02/27/2008 | EP1891028A1 Non-peptidic inhibitors of akap/pka interaction |
| 02/27/2008 | EP1891027A1 Processes for the preparation of stable polymorphic form i of ritonavir |
| 02/27/2008 | EP1891017A1 Nitrogen heterocycle biaryls for osteoporosis and other diseases |
| 02/27/2008 | EP1891013A1 Tetrahydroquinoline derivatives |
| 02/27/2008 | EP1891012A2 Quinoline derivatives as nk3 anatgonists |
| 02/27/2008 | EP1891011A1 Tetrahydroquinolines used in the form of modulators of mitotic motor-proteins eg5 |
| 02/27/2008 | EP1891010A2 A process for the preparation of an injectable solution of (2s)-n-(2;6-dimethyl-phenyl)-1-propyl-2-piperidincarboxamide |
| 02/27/2008 | EP1891008A1 Oxindoles as kinase inhibitors |
| 02/27/2008 | EP1891007A1 Indole derivatives having antitumor activity |
| 02/27/2008 | EP1891006A2 Inhibitors of cytosolic phospholipase a2 |
| 02/27/2008 | EP1891004A1 Pentafluorosulphanyl-substituted compound and its use for producing medicaments |
| 02/27/2008 | EP1891003A1 Fluoroalkylamine derivatives as cathepsin inhibitors |
| 02/27/2008 | EP1891002A1 Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |
| 02/27/2008 | EP1891001A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS |
| 02/27/2008 | EP1890997A1 Methods of purifying tigecycline |
| 02/27/2008 | EP1890995A2 Synthesis of organic compounds |